Associated Papers
Characterisation of pharmacogenomic variation in the Shetland and Orkney Isles in Scotland.
Twesigomwe D et al.
Scientific Reports, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Identification of New Substrates and Inhibitors of Human CYP2A7.
Ashraf RA et al.
Molecules (basel, Switzerland), 2024
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes.
El-Boraie A et al.
Clinical and Translational Science, 2022
Genomic and transcriptomic profiling of carcinogenesis in patients with familial adenomatous polyposis.
Li J et al.
Gut, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Variation in CYP2A6 Activity and Personalized Medicine.
Tanner JA et al.
Journal of Personalized Medicine, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.
Hosono H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2017
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.
López-Flores LA et al.
Excli Journal, 2017
Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.
Wang TH et al.
The Aaps Journal, 2014
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Bienvenu E et al.
Antiviral Research, 2014
Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.
Umamaheswaran G et al.
The Indian Journal of Medical Research, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans.
Djordjevic N et al.
Drug Metabolism and Pharmacokinetics, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Cytochrome p450 metabolism of betel quid-derived compounds: implications for the development of prevention strategies for oral and pharyngeal cancers.
Lin CY et al.
Thescientificworldjournal, 2013
Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).
Han S et al.
Biological & Pharmaceutical Bulletin, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line.
Lee HJ et al.
Toxicological Research, 2011
In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.
Djordjevic N et al.
European Journal of Clinical Pharmacology, 2010
Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI et al.
European Journal of Clinical Pharmacology, 2009
Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research.
Wall TL et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 2007
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
Gresner P et al.
Lung Cancer (amsterdam, Netherlands), 2007
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M et al.
Clinical Pharmacology and Therapeutics, 2006
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
Al Koudsi N et al.
European Journal of Clinical Pharmacology, 2006
Identification and analysis of deleterious human SNPs.
Yue P et al.
Journal of Molecular Biology, 2006
CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro.
Rossini A et al.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologica, 2006
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M et al.
Pharmacogenetics and Genomics, 2005
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M et al.
Drug Metabolism and Pharmacokinetics, 2005
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T et al.
Clinical Pharmacology and Therapeutics, 2004
Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
Yamanaka H et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2004
Novel human CYP2A6 alleles confound gene deletion analysis.
Nakajima M et al.
Febs Letters, 2004
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R et al.
Clinical Pharmacology and Therapeutics, 2003
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
Tricker AR
Toxicology, 2003
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
Yoshida R et al.
British Journal of Clinical Pharmacology, 2002
Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
Nakajima M et al.
Drug Metabolism Reviews, 2002
Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant.
Zhang X et al.
The Journal of Pharmacology and Experimental Therapeutics, 2002
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Tyndale RF et al.
Therapeutic Drug Monitoring, 2002
Polymorphisms of CYP2A6 and its practical consequences.
Raunio H et al.
British Journal of Clinical Pharmacology, 2001